News and Trends 7 Sep 2022 Lesaffre acquires genome editing company Recombia Biosciences Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Gene therapies for lung cancer identified by international team of scientists Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […] August 24, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 10 Aug 2022 How the UK precision breeding bill could unshackle gene editing The U.K. is considering lowering restrictions on gene-edited crops. PacBio’s Neil Ward explains how the changes could impact the gene editing landscape. CRISPR gene editing technology has changed the game in the biotech industry by making it easier than ever before to make small changes to the genome. In addition to myriad healthcare applications, the […] August 10, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Epigenic Therapeutics raises $20M for gene editing technology Epigenic Therapeutics Co., Ltd., a Chinese biotech gene editing company, has secured $20 million in Series Angel and Pre-A funding. The Series Pre-A funding came from investments by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating. The proceeds will be used to advance the company’s […] August 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies Poseida Therapeutics, Inc. has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel off-the-shelf cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications. “We are excited […] August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 26 Jul 2022 How DNA sequencing can safeguard against biodiversity loss Preserving Earth’s biodiversity is crucial as we rely on healthy ecosystems for many services, from clean air and water to protection from floods and pandemics. DNA sequencing is an invaluable tool for characterizing biodiversity and informing conservation efforts. In Earth’s history, there have been five major mass extinction events — the most recent of which […] July 26, 2022 - 8 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Replay launches with $55M to reprogram biology by writing and delivering big DNA Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has launched with $55 million in seed financing. The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial. Replay, which is based in San Diego, Cal., and London, U.K., […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services Solid tumor assays have been launched by Mission Bio Inc., through its Pharma Assay Development (PAD) services. The availability of this new service offering from Mission Bio, a high-throughput single-cell DNA and multi-omics analysis company, will help accelerate the development of cancer therapeutics. It will do so by reducing the time and cost associated with […] July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2022 World’s first research project for an early detection, multi-cancer screening test launched in Singapore A project for the discovery and validation of new combinations of biomarkers that can detect multi-cancer early has been launched in Singapore. Biotechnology company, MiRXES Ptr Ltd, announced this week the signing of a memorandum of understanding signaling the launch of Project CADENCE (Cancer Detected Early caN be CurEd). It is the world’s first large-scale […] July 8, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Poxel publishes ALD studies Two preclinical articles have been published in different journals for treatments being developed by French biopharmaceutical company, Poxel. Poxel develops treatments for chronic, serious diseases with metabolic pathophysiology including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The articles have been about genetic disease X-Linked Adrenoleukodystrophy (ALD) and molecules PXL065 and PXL770. These molecules have separate […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 7 Mar 2022 Multiplexing Speeds up Writing and Editing DNA While scientists can read DNA fast, editing and writing it is not that easy. Increasing the speed of editing and writing DNA sequences will be critical to ushering in new applications of genome engineering. Much of biotech is about reverse-engineering the designs that billions of years of evolution have put together. To be able to […] March 7, 2022 - 6 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2022 Ribbon Biolabs Pushes DNA Synthesis Length Limits with €18M Series A The Viennese biotech startup Ribbon Biolabs has raised an €18M Series A round to reduce the costs of synthesizing long DNA molecules, which could accelerate research into synthetic biology and the storage of data as DNA. Supported by lead investor Hadean Ventures, Ribbon Biolabs’ fundraising round is part and parcel of a continuing investor interest […] February 1, 2022 - 3 minutesmins - By Dan Samorodnitsky Share WhatsApp Twitter Linkedin Email